Zacks.com Quotes and Research

GILEAD SCIENCES INC (NASD)
GILD 46.98 0.02 (0.04%) Vol.  2,637,844 16:00 ET

Day Low - High 46.72 - 47.12
52wk Low - High 40.62 - 53.28
Avg Volume 7,504,385
Industry MED-BIOMED/GENE
Market Cap 42.46 B
Div - Yield 0.00 - 0.00
PE (forward) 17.04
PEG Ratio 1.07
Current Year Est. 2.76
EPS Last Year 2.62
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 10/22/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
GILEAD SCIENCES INC GILD PREMIUM
DISCOVERY LABS DSCO PREMIUM
TELIK INC TELK PREMIUM
NANOSPHERE INC NSPH PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.46
ABR (Last Week) 1.46
# of Recs in ABR 35
Average Target Price 55.35
Industry Rank by ABR 49 out of 217
Rank in Industry 65 out of 172
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate GILD?
Buy
Sell
Find out what the Zacks Community
thinks of GILD at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR GILD
Zacks Blog: Gilead Awaits Committee Outcome
Nov 13, 2009
Zacks Blog: Zacks Industry Outlook Highlights: Alcon, Novartis, Gilead Sciences, Biogen Idec and Acorda Therapeutics
Nov 10, 2009
Zacks Blog: United Therapeutics Misses
Nov 02, 2009
Zacks Blog: Gilead’s Positive Data
Nov 02, 2009
Zacks Equity Research: Report for GILD
Oct 22, 2009
More Zacks Commentary
NEWS
Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program
Nov 24, 2009
Gilead, GSK Announce Viread Agreement In Asia (GILD,GSK)
Nov 24, 2009
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Nov 24, 2009
Fundamental and Technical Research for SFD, RHI, PFG, PDLI, GILD andFUQI Posted on BenchmarkJournal.com Today
Nov 18, 2009
Gilead Sciences to Present at the Lazard Capital Markets Annual Healthcare Conference
Nov 17, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 0.79 0.78 2.76 3.13
Number of Estimates 28 9 24 28
Low Estimates 0.66 0.71 2.65 2.90
High Estimate 0.90 0.85 2.86 3.61
Year Ago EPS 0.60 0.63 2.11 2.76
EPS Growth 32.26% 23.28% 30.59% 13.58%

More Estimates

COMPANY DESCRIPTION
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.

Full Company Report
FINANCIALS
EPS TTM 2.62
Sales 5335.75
Net Income 2399.2
Price/Earnings 17.92
Price/Book 7.38
Price/Cash Flow 20.16
Price/Sales 6.63


More Financials